

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



山東威高集團醫用高分子製品股份有限公司  
Shandong Weigao Group Medical Polymer Company Limited \*

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1066)**

**VOLUNTARY ANNOUNCEMENT  
POSSIBLE SPIN-OFF AND SEPARATE LISTING OF THE  
BUSINESS FOCUSING ON DISPOSABLE MEDICAL  
DEVICES FOR VASCULAR AND CANCER-RELATED  
INTERVENTIONAL PROCEDURES**

This announcement is made by 山東威高集團醫用高分子製品股份有限公司 Shandong Weigao Group Medical Polymer Company Limited\* (the “**Company**”) on a voluntary basis.

The Company is considering a possible spin-off and separate listing of its business in the research and development, manufacturing, and sale and distribution of disposable medical devices for radiology, vascular, cardiology and oncology interventional procedures (the “**Spin-off Business**”) on a recognized stock exchange (the “**Possible Spin-off and Listing**”).

In the event that the Company proceeds with the Possible Spin-off and Listing, it will constitute a spin-off of the Spin-off Business by the Company subject to compliance with Practice Note 15 to the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) and will also be a deemed disposal of an interest in the Spin-off Business by the Company under Rule 14.29 of the Listing Rules.

The Company will make further announcement(s) as and when appropriate in compliance with the requirements of the Listing Rules.

As at the date of this announcement, the details of the Possible Spin-off and Listing have not been finalised. Shareholders of the Company and potential investors should note that the Possible Spin-off and Listing is subject to, among others, approvals from the relevant regulatory authorities and market conditions. There is no assurance that the Possible Spin-off and Listing will proceed or as to when it may take place. Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board  
**Shandong Weigao Group Medical Polymer Company Limited**  
**Zhang Hua Wei**  
*Chairman*

Weihai, Shandong, the PRC, 14 September 2020

*As at the date of this announcement, the Board comprises:*

Mr. Zhang Hua Wei (*Executive Director*)

Mr. Long Jing (*Executive Director*)

Mr. Wang Yi (*Executive Director*)

Mr. Gong Jian Bo (*Executive Director*)

Mrs. Zhou Shu Hua (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Ming Zhong (*Independent non-executive Director*)

Mrs. Wang Jin Xia (*Independent non-executive Director*)

\* *for identification purposes only*